Literature DB >> 15021224

Glaucoma management in developing countries: medical, laser, and surgical options for glaucoma management in countries with limited resources.

Ravi Thomas1, G Chandra Sekhar, Rajesh S Kumar.   

Abstract

PURPOSE OF REVIEW: Most people affected by glaucoma live in developing countries. Recent trials and reports provide sound evidence for management of glaucoma. This review extrapolates relevant articles to the developing world. RECENT
FINDINGS: The predictive value of gonioscopy for progression of primary angle closure suspects (PACS) to primary angle closure (PAC) is only 22% (95% CI: 9.80-34.2). PACS are not uncommon; laser peripheral iridotomy (LPI) is neither indicated nor feasible for all. Twenty-eight and a half percent of PAC progress to primary angle closure glaucoma; the number needed to treat (NNT) for LPI to prevent progression is only 4. Laser peripheral iridoplasty controls acute angle closure glaucoma (AACG) faster than medical therapy alone. Primary lens extraction has also been suggested as treatment for AACG after control of the acute attack. A 5-year NNT for ocular hypertension (OH) of 20 is too high to allow treatment of all OH. High-risk OH and primary open angle glaucoma (POAG) have an NNT of 5 to 6 and merit treatment. Latanoprost and brimonidine are effective in lowering IOP in Asian eyes with POAG, but primary surgical therapy may be a more viable option. For cataract and coexistent glaucoma requiring filtration, trabeculectomy combined with the Blumenthal technique of cataract surgery may be as effective as trabeculectomy combined with phacoemulsification.
SUMMARY: The principles of glaucoma management should be the same the world over. Considering the paucity of resources and competing opportunity costs, countries with limited resources have to extrapolate available information in a sensible and cost-effective manner.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15021224     DOI: 10.1097/00055735-200404000-00012

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  9 in total

1.  Glaucoma in the developing world.

Authors:  Mahesh Ramchandani
Journal:  BMJ       Date:  2006-11-04

2.  Surgical outcome of safe surgery system trabeculectomy combined with cataract extraction.

Authors:  R R Khandelwal; D Raje; A Rathi; A Agashe; M Majumdar; R Khandelwal
Journal:  Eye (Lond)       Date:  2014-12-12       Impact factor: 3.775

3.  Global rates of glaucoma surgery.

Authors:  Kaweh Mansouri; Felipe A Medeiros; Robert N Weinreb
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-09-26       Impact factor: 3.117

4.  Socioeconomics of long-term glaucoma therapy in India.

Authors:  Bhagabat Nayak; Shikha Gupta; Guresh Kumar; Tanuj Dada; Viney Gupta; Ramanjit Sihota
Journal:  Indian J Ophthalmol       Date:  2015-01       Impact factor: 1.848

5.  Changes in choroidal thickness after prophylactic iridectomy in primary angle closure suspect eyes using enhanced depth imaging optical coherence tomography.

Authors:  Wei Wang; Minwen Zhou; Wenbin Huang; Xinbo Gao; Xiulan Zhang
Journal:  Indian J Ophthalmol       Date:  2015-10       Impact factor: 1.848

6.  What Glaucoma Surgical Rate could Serve as a Target for West Africa? A Systematic Review.

Authors:  Egbula N Eni; Winifred Nolan; Bassey Eval; John C Buchan
Journal:  J Curr Glaucoma Pract       Date:  2021 Jan-Apr

7.  Medical management of primary open-angle glaucoma: Best practices associated with enhanced patient compliance and persistency.

Authors:  Sadhana V Kulkarni; Karim F Damji; Yvonne M Buys
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

Review 8.  Glaucoma in developing countries.

Authors:  Ravi Thomas
Journal:  Indian J Ophthalmol       Date:  2012 Sep-Oct       Impact factor: 1.848

9.  Predictive value of early postoperative IOP and bleb morphology in Mitomycin-C augmented trabeculectomy.

Authors:  Hamed Esfandiari; Mohammad Pakravan; Nils A Loewen; Mehdi Yaseri
Journal:  F1000Res       Date:  2017-10-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.